cartitude-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
Published 1 year ago • 57 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
8:16
results from cartitude-4: cilta-cel for lenalidomide-refractory multiple myeloma
-
1:21
an update on cartitude-2: cilta-cel in patients with multiple myeloma in second line
-
2:18
a cost per responder analysis of cilta-cel vs physician's choice in lenalidomide-refractory mm
-
1:17
efficacy & safety of standard of care cilta-cel in r/r multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
21:38
drawing the line: the rationale behind blood tube collection order
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
5:05
patient-reported outcomes in cartitude-4: cilta-cel vs soc in r/r multiple myeloma
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
1:54
cilta-cel vs standard of care in functional high-risk myeloma: findings from cartitude-4
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
2:32
final results of cartitude-1: cilta-cel in heavily pretreated patients with r/r multiple myeloma
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma
-
2:31
cilta-cel achieves deep and durable responses for r/r multiple myeloma
-
5:44
cilta-cel in r/r myeloma: preliminary results from cartitude-1
-
1:33
ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor
-
1:03
insights into the cartitude-6 trial: rationale and design
-
2:31
the role of cilta-cel in the myeloma treatment landscape
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
1:09
medical writing bias in myeloma clinical research